Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC

Simple item page
dc.contributor.authorGettinger, S.
dc.contributor.authorBorghaei, H.
dc.contributor.authorBrahmer, J.
dc.contributor.authorChow, L.
dc.contributor.authorBurgio, M.
dc.contributor.authorDe Castro Carpeno, J.
dc.contributor.authorPluzanski, A.
dc.contributor.authorArrieta, O.
dc.contributor.authorAren Frontera, O.
dc.contributor.authorChiari, R.
dc.contributor.authorButts, C.
dc.contributor.authorWojcik-Tomaszewska, J.
dc.contributor.authorCoudert, B.
dc.contributor.authorGarassino, M.
dc.contributor.authorReady, N.
dc.contributor.authorFelip, E.
dc.contributor.authorAlonso Garcia, M.
dc.contributor.authorWaterhouse, D.
dc.contributor.authorDomine, M.
dc.contributor.authorBarlesi, F.
dc.contributor.authorAntonia, S.
dc.contributor.authorWohlleber, M.
dc.contributor.authorGerber, D.
dc.contributor.authorCzyzewicz, G.
dc.contributor.authorSpigel, D.
dc.contributor.authorCrino, L.
dc.contributor.authorEberhardt, W.
dc.contributor.authorLi, A.
dc.contributor.authorMarimuthu, S.
dc.contributor.authorVokes, E.
dc.contributor.authoraffiliation[Gettinger, S.] Yale Comprehens Canc Ctr, New Haven, CT USA
dc.contributor.authoraffiliation[Borghaei, H.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
dc.contributor.authoraffiliation[Brahmer, J.] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
dc.contributor.authoraffiliation[Chow, L.] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA
dc.contributor.authoraffiliation[Burgio, M.] Ist Sci Romagnolo Studio & Cura Tumori Irst Irccs, Meldola, Italy
dc.contributor.authoraffiliation[Crino, L.] Ist Sci Romagnolo Studio & Cura Tumori Irst Irccs, Meldola, Italy
dc.contributor.authoraffiliation[De Castro Carpeno, J.] Ciocc, Hosp Madrid, Norte Sanchinarro, Madrid, Spain
dc.contributor.authoraffiliation[Pluzanski, A.] Maria Sklodowska Curie Inst Oncol, Warsaw, Poland
dc.contributor.authoraffiliation[Arrieta, O.] Inst Nacl Cancerol, Mexico City, DF, Mexico
dc.contributor.authoraffiliation[Aren Frontera, O.] Ctr Invest Clin Bradford Hill, Santiago, Chile
dc.contributor.authoraffiliation[Chiari, R.] Osped S Maria Misericordia, Perugia, Italy
dc.contributor.authoraffiliation[Butts, C.] Cross Canc Inst, Edmonton, AB, Canada
dc.contributor.authoraffiliation[Wojcik-Tomaszewska, J.] Prov Ctr Oncol Gdansk, Gdansk, Poland
dc.contributor.authoraffiliation[Coudert, B.] Ctr Georges Francois Leclerc, Dijon, France
dc.contributor.authoraffiliation[Garassino, M.] Inst Nazl Studio & Cura, Milan, Italy
dc.contributor.authoraffiliation[Ready, N.] Duke Univ, Med Ctr, Durham, NC USA
dc.contributor.authoraffiliation[Felip, E.] Hosp Gen Univ Vall DHebron, Barcelona, Spain
dc.contributor.authoraffiliation[Alonso Garcia, M.] Hosp Univ Virgen Del Rocio, Seville, Spain
dc.contributor.authoraffiliation[Waterhouse, D.] Oncol Hematol Care Inc, Cincinnati, OH USA
dc.contributor.authoraffiliation[Domine, M.] Iis Fjd, Hosp Univ Fdn Jimenez Diaz, Madrid, Spain
dc.contributor.authoraffiliation[Barlesi, F.] Aix Marseille Univ, Crcm, Aphm, Cnrs,Inserm, Marseille, France
dc.contributor.authoraffiliation[Antonia, S.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
dc.contributor.authoraffiliation[Wohlleber, M.] Robert Bosch Canc Ctr, Gerlingen, Germany
dc.contributor.authoraffiliation[Gerber, D.] UT Southwestern Med Ctr, Dallas, TX USA
dc.contributor.authoraffiliation[Czyzewicz, G.] John Paul 2 Hosp, Krakow, Poland
dc.contributor.authoraffiliation[Spigel, D.] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
dc.contributor.authoraffiliation[Eberhardt, W.] Univ Med Essen, Essen, Germany
dc.contributor.authoraffiliation[Eberhardt, W.] Ruhrlandklin, Essen, Germany
dc.contributor.authoraffiliation[Li, A.] Bristol Myers Squibb, Lawrence Township, NJ USA
dc.contributor.authoraffiliation[Marimuthu, S.] Bristol Myers Squibb, Lawrence Township, NJ USA
dc.contributor.authoraffiliation[Vokes, E.] Univ Chicago, Med & Biol Sci Div, Chicago, IL 60637 USA
dc.date.accessioned2025-01-07T15:34:34Z
dc.date.available2025-01-07T15:34:34Z
dc.date.issued2019-10-01
dc.identifier.doi10.1016/j.jtho.2019.08.486
dc.identifier.essn1556-1380
dc.identifier.issn1556-0864
dc.identifier.unpaywallURLhttp://www.jto.org/article/S1556086419311694/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27253
dc.identifier.wosID492162201171
dc.issue.number10
dc.issue.numberS
dc.journal.titleJournal of thoracic oncology
dc.journal.titleabbreviationJ. thorac. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS244-S245
dc.publisherElsevier science inc
dc.rights.accessRightsopen access
dc.subjectnivolumab
dc.subject5-year overall survival
dc.subjectadvanced non-small cell lung cancer
dc.titleFive-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number14
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía